Skip to main content

HCPCS Level II

HCPCS Level II 2010 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2010, grouped by effective date. Each code's own page carries its full record.

111
Added
0
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2010 (97)

  • A4264 — Permanent implantable contraceptive intratubal occlusion device(s) and delivery system
  • A4336 — Incontinence supply, urethral insert, any type, each
  • A4360 — Disposable external urethral clamp or compression device, with pad and/or pouch, each
  • A4456 — Adhesive remover, wipes, any type, each
  • A4466 — Garment, belt, sleeve or other covering, elastic or similar stretchable material, any type, each
  • A9581 — Injection, gadoxetate disodium, 1 ml
  • A9582 — Iodine i-123 iobenguane, diagnostic, per study dose, up to 15 millicuries
  • A9583 — Injection, gadofosveset trisodium, 1 ml
  • A9604 — Samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries
  • C9254 — Injection, lacosamide, 1 mg
  • C9257 — Injection, bevacizumab, 0.25 mg
  • E0433 — Portable liquid oxygen system, rental; home liquefier used to fill portable liquid oxygen containers, includes portable containers, regulator, flowmeter, humidifier, cannula or mask and tubing, with or without supply reservoir and contents gauge
  • E1036 — Multi-positional patient transfer system, extra-wide, with integrated seat, operated by caregiver, patient weight capacity greater than 300 lbs
  • G0420 — Face-to-face educational services related to the care of chronic kidney disease; individual, per session, per one hour
  • G0421 — Face-to-face educational services related to the care of chronic kidney disease; group, per session, per one hour
  • G0422 — Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session
  • G0423 — Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session
  • G0424 — Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day
  • G0425 — Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth
  • G0426 — Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth
  • G0427 — Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth
  • G0431 — Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter
  • G8545 — I intend to report the hepatitis c measures group
  • G8547 — I intend to report the ischemic vascular disease (ivd) measures group
  • G8548 — I intend to report the heart failure (hf) measures group
  • G8549 — All quality actions for the applicable measures in the hepatitis c measures group have been performed for this patient
  • G8551 — All quality actions for the applicable measures in the heart failure (hf) measures group have been performed for this patient
  • G8552 — All quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient
  • G8559 — Patient referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation
  • G8560 — Patient has a history of active drainage from the ear within the previous 90 days
  • G8561 — Patient is not eligible for the referral for otologic evaluation for patients with a history of active drainage measure
  • G8562 — Patient does not have a history of active drainage from the ear within the previous 90 days
  • G8563 — Patient not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
  • G8564 — Patient was referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not specified)
  • G8565 — Verification and documentation of sudden or rapidly progressive hearing loss
  • G8566 — Patient is not eligible for the "referral for otologic evaluation for sudden or rapidly progressive hearing loss" measure
  • G8567 — Patient does not have verification and documentation of sudden or rapidly progressive hearing loss
  • G8568 — Patient was not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
  • G8569 — Prolonged postoperative intubation (> 24 hrs) required
  • G8570 — Prolonged postoperative intubation (> 24 hrs) not required
  • G8571 — Development of deep sternal wound infection/mediastinitis within 30 days postoperatively
  • G8572 — No deep sternal wound infection/mediastinitis
  • G8573 — Stroke following isolated cabg surgery
  • G8574 — No stroke following isolated cabg surgery
  • G8575 — Developed postoperative renal failure or required dialysis
  • G8576 — No postoperative renal failure/dialysis not required
  • G8577 — Re-exploration required due to mediastinal bleeding with or without tamponade, unplanned coronary artery intervention (native, vessel, graft, or both), valve dysfunction, aortic reintervention, or other cardiac reason
  • G8578 — Re-exploration not required due to mediastinal bleeding with or without tamponade, unplanned coronary artery intervention (native, vessel, graft, or both), valve dysfunction, aortic reintervention, or other cardiac reason
  • G8579 — Antiplatelet medication at discharge
  • G8580 — Antiplatelet medication contraindicated
  • G8581 — No antiplatelet medication at discharge
  • G8582 — Beta-blocker at discharge
  • G8583 — Beta-blocker contraindicated
  • G8584 — No beta-blocker at discharge
  • G8585 — Anti-lipid treatment at discharge
  • G8586 — Anti-lipid treatment contraindicated
  • G8587 — No anti-lipid treatment at discharge
  • G8593 — Lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
  • G8594 — Lipid profile not performed, reason not given
  • G8595 — Most recent ldl-c < 100 mg/dl
  • G8597 — Most recent ldl-c >= 100 mg/dl
  • G8598 — Aspirin or another antiplatelet therapy used
  • G8599 — Aspirin or another antiplatelet therapy not used, reason not given
  • G8600 — Iv thrombolytic therapy initiated within 4.5 hours (<= 270 minutes) of time last known well
  • G8601 — Iv thrombolytic therapy not initiated within 4.5 hours (<= 270 minutes) of time last known well for reasons documented by clinician (e.g. patient enrolled in clinical trial for stroke, patient admitted for elective carotid intervention)
  • G8602 — Iv thrombolytic therapy not initiated within 4.5 hours (<= 270 minutes) of time last known well, reason not given
  • G8627 — Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)
  • G8628 — Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power iol, retinal detachment, or wound dehiscence)
  • J0461 — Injection, atropine sulfate, 0.01 mg
  • J0586 — Injection, abobotulinumtoxina, 5 units
  • J0598 — Injection, c-1 esterase inhibitor (human), cinryze, 10 units
  • J0833 — Injection, cosyntropin, not otherwise specified, 0.25 mg
  • J0834 — Injection, cosyntropin, 0.25 mg
  • J2562 — Injection, plerixafor, 1 mg
  • J2793 — Injection, rilonacept, 1 mg
  • J2796 — Injection, romiplostim, 10 micrograms
  • J7185 — Injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u.
  • J7325 — Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg
  • J9155 — Injection, degarelix, 1 mg
  • J9171 — Injection, docetaxel, 1 mg
  • J9328 — Injection, temozolomide, 1 mg
  • L2861 — Addition to lower extremity joint, knee or ankle, concentric adjustable torsion style mechanism for custom fabricated orthotics only, each
  • L3891 — Addition to upper extremity joint, wrist or elbow, concentric adjustable torsion style mechanism for custom fabricated orthotics only, each
  • L5973 — Endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, includes power source
  • L8031 — Breast prosthesis, silicone or equal, with integral adhesive, any type
  • L8032 — Nipple prosthesis, prefabricated, reusable, any type, each
  • L8627 — Cochlear implant, external speech processor, component, replacement
  • L8628 — Cochlear implant, external controller component, replacement
  • L8629 — Transmitting coil and cable, integrated, for use with cochlear implant device, replacement
  • L8692 — Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment
  • Q0138 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
  • Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
  • Q0506 — Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
  • Q4074 — Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms
  • Q9968 — Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg
  • S0280 — Medical home program, comprehensive care coordination and planning, initial plan
  • S0281 — Medical home program, comprehensive care coordination and planning, maintenance of plan

Added effective March 23, 2010 (1)

  • G0429 — Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

Added effective May 25, 2010 (1)

  • G0428 — Collagen meniscus implant procedure for filling meniscal defects (e.g., cmi, collagen scaffold, menaflex)

Added effective July 1, 2010 (2)

  • C9800 — Dermal injection procedure(s) for facial lipodystrophy syndrome (lds) and provision of radiesse or sculptra dermal filler, including all items and supplies
  • Q2026 — Injection, radiesse, 0.1 ml

Added effective October 1, 2010 (10)

  • C1749 — Endoscope, retrograde imaging/illumination colonoscope device (implantable)
  • C8931 — Magnetic resonance angiography with contrast, spinal canal and contents
  • C8932 — Magnetic resonance angiography without contrast, spinal canal and contents
  • C8933 — Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
  • C8934 — Magnetic resonance angiography with contrast, upper extremity
  • C8935 — Magnetic resonance angiography without contrast, upper extremity
  • C8936 — Magnetic resonance angiography without contrast followed by with contrast, upper extremity
  • Q5010 — Hospice home care provided in a hospice facility
  • S0148 — Injection, pegylated interferon alfa-2b, 10 mcg
  • S0169 — Calcitrol, oral, 0.25 microgram

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2010
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger